12:33 PM EST - BioVaxys Technology Corp : Announces highly promising results from a two-arm phase 1 clinical study of the safety and immunogenicity of both its maveropepimut-S (MVP-S) and DPX-SurMAGE cancer vaccines in patients with non-muscle invasive bladder cancer. Treatment with either MVP-S or DPX-SurMAGE was shown to be well tolerated, with both products inducing significant systemic antigen-specific T cell responses, which is a critical goal in cancer immunotherapy. BioVaxys Technology Corp
shares C.BIOV are trading up $0.02 at $0.24.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=BIOV%3ACC&qmodStoryID=7662705396215534
